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Background: The porcine reproductive and respiratory syndrome virus (PRRSV) is a rapidly evolving pathogen of
swine. At present, there is a high demand for safe and more effective vaccines that can be adapted regularly to
emerging virus variants. A recent study showed that, by the use of a controlled inactivation procedure, an
experimental BEI-inactivated PRRSV vaccine can be developed that offers partial protection against homologous
challenge with the prototype strain LV. At present, it is however not known if this vaccine can be adapted to
currently circulating virus variants. In this study, two recent PRRSV field isolates (07 V063 and 08 V194) were used for
BEI-inactivated vaccine production. The main objective of this study was to assess the efficacy of these
experimental BEI-inactivated vaccines against homologous and heterologous challenge and to compare it with an
experimental LV-based BEI-inactivated vaccine and commercial inactivated and attenuated vaccines. In addition, the
induction of challenge virus-specific (neutralizing) antibodies by the different vaccines was assessed.
Results: In a first experiment (challenge with 07 V063), vaccination with the experimental homologous (07 V063)
inactivated vaccine shortened the viremic phase upon challenge with approximately 2 weeks compared to the
mock-vaccinated control group. Vaccination with the commercial attenuated vaccines reduced the duration of
viremia with approximately one week compared to the mock-vaccinated control group. In contrast, the
experimental heterologous (LV) inactivated vaccine and the commercial inactivated vaccine did not influence
viremia. Interestingly, both the homologous and the heterologous experimental inactivated vaccine induced
07 V063-specific neutralizing antibodies upon vaccination, while the commercial inactivated and attenuated
vaccines failed to do so.
In the second experiment (challenge with 08 V194), use of the experimental homologous (08 V194) inactivated
vaccine shortened viremia upon challenge with approximately 3 weeks compared to the mock-vaccinated control
group. Similar results were obtained with the commercial attenuated vaccine. The experimental heterologous
(07 V063 and LV) inactivated vaccines did not significantly alter viremia. In this experiment, 08 V194-specific
neutralizing antibodies were induced by the experimental homologous and heterologous inactivated vaccines and
a faster appearance post challenge was observed with the commercial attenuated vaccine.
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Conclusions: The experimental homologous inactivated vaccines significantly shortened viremia upon challenge.
Despite the concerns regarding the efficacy of the commercial attenuated vaccines used on the farms where the
field isolates were obtained, use of commercial attenuated vaccines clearly shortened the viremic phase upon
challenge. In contrast, the experimental heterologous inactivated vaccines and the commercial inactivated vaccine
had no or only a limited influence on viremia. The observation that homologous BEI-inactivated vaccines can
provide a more or less standardized, predictable degree of protection against a specific virus variant suggests that
such vaccines may prove useful in case virus variants emerge that escape the immunity induced by the attenuated
vaccines.Background
Porcine reproductive and respiratory syndrome virus
(PRRSV) infection is characterized by reproductive failure
in sows, and is associated with respiratory problems in
pigs of all ages [1-7]. With few exceptions, PRRSV is
present in a majority of swine-producing countries around
the world and gives rise to significant economic losses in
the swine industry [8]. Based on genetic and antigenic
analysis, two PRRSV genotypes are recognized: a Euro-
pean (EU) genotype (prototype: Lelystad virus, LV) [9] and
a North American (NA) genotype (prototype: VR2332),
which share about 55–70% nucleotide homology [10].
However, a high genetic variability has been demonstrated
within both genotypes [10-13] and the genetic differences
between virus variants are mirrored in different virulence,
pathogenicity, immunogenicity, . . . A recent study by Diaz
et al. (2012) showed that infection with different PRRSV
strains leads to different virological and immunological
outcomes and results in different degrees of homologous
and heterologous protection [14]. Another study by
Martinez-Lobo and coworkers (2011) reported that differ-
ent PRRSV isolates differ in their susceptibility to antibody
neutralization [15]. Evidently, the high variability of the
virus represents a major hurdle for effective PRRSV pre-
vention and control [16]. Since PRRSV poses a serious
burden on the swine industry worldwide, the need for effi-
cient control measures is high. A variety of PRRS eradica-
tion strategies have been described, including total
depopulation/repopulation, partial depopulation, segre-
gated early weaning, test and removal and herd closure.
Also planned exposure to a farm-specific virus isolate is a
common strategy in the United States and Canada [17].
This last approach is often performed without monitoring
and is consequently unreliable in getting the targeted
population homogeneously infected in a timely manner.
While the above strategies can certainly be useful, it is also
clear that efficient PRRSV vaccines are extremely valuable
tools to minimize the clinical and economical impact of
PRRSV infections. However, the commonly used vaccines,
both attenuated and inactivated, are not without their pro-
blems. Although attenuated vaccines have the potential to
protect animals against viremia, the degree of protectiondepends on various factors, including the homology be-
tween the vaccine virus and the circulating virus [18]. In
addition, there are some safety concerns, as the vaccine
virus may spread and revert to virulence [19-22]. The
commercially available inactivated vaccines are generally
safe to use, but do not provide sufficient protection
[21,23,24]. In addition, the ability of PRRSV to subvert the
host immune system further complicates these matters.
At present, it is generally accepted that there is a need for
new and safe vaccines that can protect against infection
with those virus variants that escape immunity induced by
the currently available commercial vaccines. In this con-
text, the use of vaccine virus that is homologous to the
PRRSV variants prevalent in the herd seems to be
favourable [18]. Vanhee et al. (2009) demonstrated that,
by use of a controlled inactivation procedure and a suit-
able adjuvant, an LV-based inactivated PRRSV vaccine can
be developed that systematically induces an LV-specific
virus-neutralizing (VN) antibody response upon 2 vacci-
nations in naïve piglets. Following homologous challenge
of the vaccinated pigs with LV, animals developed an earl-
ier and strongly elevated VN antibody response and a sig-
nificant reduction of viremia was observed [25]. Currently
however, it is unknown whether it is possible to achieve
similar results for PRRSV isolates that are currently caus-
ing reproductive or respiratory disorders in the field. Two
recent PRRSV isolates, from outbreaks in herds vaccinated
with a registered vaccine, were used for autogenous inacti-
vated vaccine development. The main objective of this
study was to test the capacity of experimental inactivated
autogenous PRRSV vaccines to protect naïve pigs against
homologous PRRSV challenge and to compare the efficacy
of these vaccines with that of experimental heterologous
inactivated vaccines, the commercial vaccine used on the
farms, and other commercial inactivated and attenuated
vaccines.
Results
Vaccination experiment with PRRSV isolate 07 V063
Clinical examination
All animals remained in good health after they were vac-
cinated. No local or systemic vaccine side effects were
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the entire experimental period. Body temperatures fluc-
tuated in all groups and statistically significant differ-
ences were not detected. Challenge with PRRSV isolate
07 V063 induced moderate fever (higher than 39.5°C,
but not higher than 40.6°C) within 10 days post infection
in 32 out of 36 inoculated pigs. The 4 remaining animals
did not develop fever. By 11 days post challenge, fever
had disappeared in all animals.
Viremia
Upon challenge, all animals became viremic. In the adju-
vant control group (group CON), viremia was detected
from day 1 after the challenge (3 pigs out of 6) and peaked
around 10 days post challenge (dpc), with a mean virus
titer of 3.6 log10 TCID50/mL. Viremia had cleared in all
animals by 5 weeks post challenge (Figure 1, CON). In the
binary ethyleneimine (BEI) inactivated 07 V063 group
(group 07 V063i), all animals became viremic, but the
peak viremia occurred earlier (day 5) and was lower
(2.9 log10 TCID50/mL). From 10 dpc, virus was no longer
detected in the serum of any of the animals, but one ani-
mal was again viremic at day 21 post challenge (Figure 1,
07 V063i). The mean viral titer in the serum was signifi-
cantly reduced compared to the control group at days 10
and 14 (p< 0.05). In group 07 V063i, a significantly lower
number of viremic piglets was observed compared to
group CON on days 10 and 14 post challenge (p< 0.05).
In the BEI-inactivated LV vaccinated group (group LVi),
all animals became viremic after challenge, with a peak
viremia of 3.6 log10 TCID50/mL on day 7. Four weeks post
challenge, virus was not found anymore in the serum of
any of the 6 pigs (Figure 1, LVi). The virus titers were not
significantly lower than those of group CON. In the group
vaccinated with ProgressisW (group PROi), viremia was
detected in all animals, with a peak of 3.6 log10 TCID50/
mL around 10–14 dpc. The viremic phase showed a simi-
lar pattern as in group CON and virus titers were not sig-
nificantly reduced. Viremia disappeared in all animals by
5 weeks after challenge (Figure 1, PROi). In the group vac-
cinated with a single shot of PorcilisW PRRS (group POR-
att) and the group vaccinated with one dose of IngelvacW
PRRS (group INGatt), a partial reduction in viremia was
seen. Viremia peaked at 5 dpc with average titers of
3.3 log10 TCID50/mL (group PORatt) and 3.2 log10
TCID50/mL (group INGatt) (Figure 1, PORatt and
INGatt). No significant differences in mean virus titers
were detected at any time-point between groups PORatt,
INGatt and CON. Only at 5 weeks after challenge, all ani-
mals of these groups were consistently virus negative. Tak-
ing all data on viremia together, group 07 V063i was the
only group that showed a significantly shortened viremia
and a significant decrease in the number of viremic piglets
compared to the mock-vaccinated control group.07 V063-specific antibodies
In group CON, virus-specific antibodies were not
detected before challenge (Figure 2, CON). At 7 dpc,
antibodies could be detected in all animals of this con-
trol group. In 2 animals of group 07 V063i, antibodies
could already be detected at 3 weeks after the primo
vaccination. The remaining animals within this group
became seropositive after booster vaccination. From the
first week after booster vaccination until 10 days after
challenge, antibody titers in this group remained signifi-
cantly higher than in group CON (p < 0.05) (Figure 2,
07 V063i). In group LVi, virus-specific antibodies against
07 V063 were detected from 2 weeks after primo vaccin-
ation and all animals seroconverted after booster vaccin-
ation. Virus-specific antibody titers were significantly
higher in group LVi compared to group CON from
7 days post booster vaccination until 21 dpc and at
42 dpc (p < 0.05) (Figure 2, LVi). In group PROi, one ani-
mal became seropositive at 1 week after booster vaccin-
ation, while the remaining animals did not show
antibodies before challenge (Figure 2, PROi). Post chal-
lenge, the course of the antibody response of this group
was similar as in group CON. In group PORatt, virus-
specific antibodies were detected in 3 out of 6 pigs at
2 weeks after vaccination (Figure 2, PORatt). At 3 weeks
post vaccination, all animals were seropositive. Virus-
specific antibodies remained present during the entire
experiment, and the antibody titers were significantly
higher compared to group CON from 21 days post vac-
cination until 21 dpc (p < 0.05). In group INGatt, virus-
specific antibodies were found in 3 out of 6 pigs at
2 weeks after vaccination (Figure 2, INGatt). One week
later, all pigs had seroconverted and remained seroposi-
tive until the end of the experiment. Antibody titers
were significantly higher compared to group CON from
21 days post vaccination till 5 dpc. Taken together, the
courses of the IPMA antibody titers in all groups were
similar to those described in other studies [24,25].
07 V063-specific virus-neutralizing antibodies
In group CON, VN antibodies were not detected until
5 weeks post challenge. Even at 6 weeks post challenge,
not all the animals from this group were positive for VN
antibodies (Figure 3, CON). In group 07 V063i,
07 V063-specific VN antibodies were already detected
upon booster vaccination. The mean VN antibody titer
decreased immediately post challenge, but increased again
10 days after infection. Some animals had no or undetect-
able VN antibodies in the period between 2 weeks before
and 10 dpc, but after this period, VN antibodies were
detected in all animals. The mean VN antibody titer was
significantly higher compared to group CON in the period
between 1 week after booster vaccination and 5 weeks
post challenge, reaching mean values ranging from 1.1 to
Figure 1 Serum-virus titers after 07 V063 challenge for group CON (Mock-vaccinated control), 07 V063i (BEI-inactivated 07 V063), LVi
(BEI-inactivated LV), PROi (ProgressisW), PORatt (PorcilisW PRRS) and INGatt (IngelvacW PRRS MLV). Virus titers in serum (log10 TCID50/mL)
were determined by virus titration on PAM, followed by immunoperoxidase staining for the PRRSV nucleocapsid protein. "= challenge. Symbols
represent individual animals and solid lines represent mean virus titers calculated on all animals present in each group. The dashed line indicates
the mean titers for all animals in group CON. The dotted line marks the detection limit for virus titration. Mentioned in the table: # = the number
of viremic animals in the different groups at different time points. M=mean virus titer of all viremic animals in the group at different time points.
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was observed in group LVi: 07 V063-neutralizing anti-
bodies were already detected at 1 week after booster vac-
cination. VN antibody titers initially decreased post
challenge and increased again from 10 dpc. Some animalsturned negative for VN antibodies in the period between
1 week before and 10 days after the challenge, but after
this period, VN antibodies were detected in all 6 animals.
Remarkably, one animal in this group did not show neu-
tralizing antibodies earlier than 4 weeks post challenge.
Figure 2 07 V063-specific IPMA antibody titers (log2) after vaccination and 07 V063 challenge for group CON (Mock-vaccinated
control), 07 V063i (BEI-inactivated 07 V063), LVi (BEI-inactivated LV), PROi (ProgressisW), PORatt (PorcilisW PRRS) and INGatt (IngelvacW
PRRS MLV).  = primo vaccination;  = booster vaccination; "= challenge. Symbols represent individual animals and solid lines represent mean
IPMA titers calculated on all animals present in each group. The dashed line indicates the mean titers for all animals in group CON. The dotted
line marks the detection limit for the IPMA test.
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to the control group at 1 and 2 weeks after booster vaccin-
ation and at 10 and 14 dpc, reaching mean values of 3.5,
3.1, 1.9 and 2.3 log2, respectively (p < 0.05) (Figure 3, LVi).
Pigs that were vaccinated with ProgressisW (two shots),
PorcilisW PRRS (single shot) and IngelvacW PRRS (single
shot) showed a roughly similar VN antibody response as
the animals in the control group. In the PorcilisWvaccinated group, a slight increase of VN antibodies was
noticed at 5 weeks post challenge, but there were no sig-
nificant differences with group CON (Figure 3, PORatt).
In summary, both BEI-inactivated vaccines induced a
strong 07 V063-specific VN antibody response after
booster vaccination, while the commercial vaccines, both
inactivated and attenuated (EU or NA genotype), did not
induce a VN antibody response against 07 V063.
Figure 3 07 V063-neutralizing antibody titers (log2) after vaccination and 07 V063 challenge for group CON (Mock-vaccinated control),
07 V063i (BEI-inactivated 07 V063), LVi (BEI-inactivated LV), PROi (ProgressisW), PORatt (PorcilisW PRRS) and INGatt (IngelvacW PRRS
MLV).  = primo vaccination;  = booster vaccination; "= challenge. Symbols represent individual animals and solid lines represent mean SN
titers calculated on all animals present in each group. The dashed line indicates the mean titers for all animals in group CON. The dotted line
marks the detection limit for the SN test.
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Clinical examination
All animals remained in good health after they were vacci-
nated. No local or systemic vaccine side effects were noted
throughout the trial period. One pig of group PORatt2
died at day 84 at the moment of blood collection. The
daily rectal temperatures varied in all groups and no sta-
tistically significant differences were observed. Challenge
with PRRSV isolate 08 V194 induced moderate fever(higher than 39.5°C, but not higher than 40.4°C) within
7 days post infection in 24 out of 31 inoculated pigs. The
7 remaining animals did not develop fever. By 8 days post
challenge, fever had disappeared in all animals.
Viremia
Upon challenge, all animals became viremic. In the con-
trol group (group CON2), a maximum mean virus titer
of 3.8 log10 TCID50/mL was reached at 10 dpc.
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virus was no longer detectable in the serum at 4, 5 or
6 weeks after challenge, depending on the animal. Still, 1
piglet remained virus positive till 6 weeks post challenge
(Figure 4, CON2). In the BEI-inactivated 08 V194 vacci-
nated group (group 08 V194i), the viremic peak at day 5
was not reduced compared to group CON2, but the
mean virus titer at day 14 was significantly reduced
(p < 0.05) and from 21 dpc, virus could no longer be
detected in any of the piglets (Figure 4, 08 V194i). The
number of viremic piglets in group 08 V194i was signifi-
cantly lower compared to group CON2 on day 21 and
28 post challenge (p < 0.05). Mean virus titers in the
group vaccinated with BEI-inactivated LV virus (group
LVi2) were comparable to those in group CON2, reach-
ing 3.0 log10 TCID50/mL at 10 dpc, and no significant
differences could be detected at any time-point between
group LVi2 and group CON2. For 3 animals of this group,
virus was cleared from the blood at 3 weeks, for 2 others
at 4 weeks and in the remaining animal at 5 weeks post
challenge (Figure 4, LVi2). In the BEI-inactivated 07 V063
vaccinated group (group 07 V063i2), viremia was detected
in all animals, with a peak around 5–10 dpc. The viremic
phase showed a similar pattern as for group LVi2 and
viremia was also not significantly reduced compared to
group CON2. Viremia disappeared in all animals by
5 weeks after challenge (Figure 4, 07 V063i2). The mean
virus titer in the group vaccinated with PorcilisW PRRS
(group PORatt2) reached 2.7 log10 TCID50/mL at 3 days
and 2.5 log10 TCID50/mL at 5 dpc, but virus titers were
not significantly different from those in group CON2 at
these time points. At later time points however, virus titers
were significantly reduced compared to group CON2
(p< 0.05). Moreover, viremia in group PORatt2 was
already cleared at 10 dpc for 3 animals and at 28 dpc, all
animals were negative (Figure 4, PORatt2). From 14 till
28 dpc, the total number of viremic animals in group
PORatt2 was significantly lower than in group CON2
(p< 0.05). In summary, groups 08 V194i and PORatt2
showed a significantly shortened viremia and a significant
decrease in the number of viremic piglets compared to
the mock-vaccinated control group, while no such effect
was seen in groups LVi2 and 07 V063i2.
08 V194-specific antibodies
All CON2 animals had virus-specific serum antibodies
starting from 7 dpc (Figure 5, CON2). All 6 animals of
group 08 V194i seroconverted at 2 or 3 weeks after the
first vaccination. Similarly, all animals of group LVi2
showed virus-specific antibodies 2 weeks after the first
vaccination. In group 07 V063i2, 08 V194-specific anti-
bodies were detected from 2 weeks after primo vaccin-
ation and all animals seroconverted after booster
vaccination. Antibody titers in all 3 vaccinated groupswere significantly higher compared to group CON2 from
1 week after booster vaccination up till 21 dpc (p < 0.05)
(Figure 5, 08 V194i, LVi2 and 07 V063i2). After 21 dpc,
mean antibody titers in groups 08 V194i, LVi2 and
07 V063i2 remained higher compared to the control
group, although differences were not significant. In
group PORatt2, all pigs showed positive antibody titers
at 2 weeks after vaccination; the antibody titers were sig-
nificantly higher compared to group CON2 starting
from 2 weeks after vaccination up till 3 weeks post chal-
lenge (p < 0.05) (Figure 5, PORatt2). In summary, the
course of the IPMA antibody titers in all groups were
similar to those described in previous studies and the
former experiment in this study [24,25].
08 V194-specific virus-neutralizing antibodies
Starting from 21 dpc, 3 pigs of group CON2 showed a VN
antibody titer and by 35 dpc, VN antibodies had appeared
in all mock-vaccinated pigs (Figure 6, CON2). All six pigs
of group 08 V194i showed high VN antibody titers at
1 week after the booster vaccination and this remained so
until the end of the experiment (Figure 6, 08 V194i). VN
antibody titers were significantly higher in group 08 V194i
compared to group CON2 from 1 week after booster vac-
cination until 5 weeks post challenge, with mean values
ranging from 3.2 to 6.2 log2 (p < 0.05). All animals of
group LVi2 seroconverted for VN antibodies at least once
within 3 weeks after booster vaccination, but VN antibody
titers remained low and were only significantly higher
than group CON2 at 14 dpc, reaching a mean value of
2.6 log2 (p < 0.05) (Figure 6, LVi2). A similar pattern as in
group 08 V194i was observed in group 07 V063i2, where
08 V194-neutralizing antibodies could already be detected
at 1 week after booster vaccination. Two animals turned
negative for VN antibodies in the period between 2 weeks
post booster vaccination and 10 dpc, but after this period,
VN antibodies were consistently detected in all 6 animals.
The mean VN antibody titer in group 07 V063i2 was sig-
nificantly higher compared to group CON2 in the period
between 1 week after booster vaccination and 4 weeks
post challenge (except for time-point 5 dpc), reaching
mean values ranging from 2.1 to 4.7 log2 (p < 0.05)
(Figure 6, 07 V063i2). None of the animals in group POR-
att2 showed 08 V194-specific VN antibodies before chal-
lenge, but VN antibodies already appeared between 5 and
10 dpc. The mean VN antibody titer in group PORatt2
was slightly but not significantly higher compared to
group CON2 between 7 and 14 dpc, reaching a maximum
of 1.6 log2 at 14 dpc (Figure 6, PORatt2). In summary,
both BEI-inactivated 08 V194 (homologous) and 07 V063
(heterologous) vaccines induced a strong 08 V194-specific
VN antibody response upon booster vaccination, while
this was not the case for the heterologous BEI-inactivated
LV vaccine and the commercial attenuated vaccine.
Figure 4 Serum-virus titers after 08 V194 challenge for group CON2 (Mock-vaccinated control), 08 V194i (BEI-inactivated 08 V194),
LVi2 (BEI-inactivated LV), 07 V063i2 (BEI-inactivated 07 V063) and PORatt2 (PorcilisW PRRS). Virus titers in serum (log10 TCID50/mL) were
determined by virus titration on PAM, followed by immunoperoxidase staining for the PRRSV nucleocapsid protein. "= challenge. Symbols
represent individual animals and solid lines represent mean virus titers calculated on all animals present in each group. The dashed line indicates
the mean titers for all animals in group CON2. The dotted line marks the detection limit for virus titration. Mentioned in the table: # = the
number of viremic animals in the different groups at different time points. M=mean virus titer of all viremic animals in the group at different
time points.
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PRRSV causes severe reproductive disorders in sows and
boars and is associated with the porcine respiratory dis-
ease complex. The virus is difficult to control and hasbecome endemic in many major swine-producing coun-
tries, leading to tremendous economic losses worldwide
[8]. To control the disease, several commercial attenu-
ated and inactivated vaccines are currently available.
Figure 5 08 V194-specific IPMA antibody titers (log2) after vaccination and 08 V194 challenge for group CON2 (Mock-vaccinated
control), 08 V194i (BEI-inactivated 08 V194), LVi2 (BEI-inactivated LV), 07 V063i2 (BEI-inactivated 07 V063) and PORatt2 (PorcilisW
PRRS).  = primo vaccination;  = booster vaccination; "= challenge. Symbols represent individual animals and solid lines represent mean IPMA
titers calculated on all animals present in each group. The dashed line indicates the mean titers for all animals in group CON2. The dotted line
marks the detection limit for the IPMA test.
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met with variable degrees of success. Reported outbreaks
of clinical PRRS in vaccinated pigs have led to doubts
about the efficacy of currently available vaccines [26].
New vaccination strategies are needed to achieve the
goals of local and regional elimination of PRRSV and it
is generally accepted that a continuous update of vaccine
strains is necessary to reach an acceptable level ofprotection in the field, even within geographical areas of
limited size. A recent study by Vanhee et al. (2009) [25]
showed that a PRRSV LV-based BEI-inactivated vaccine
induces LV-specific VN antibodies in PRRSV-negative
animals and offers partial protection upon homologous
challenge. In that study, it was however not assessed if
such a vaccine can be adapted to field variants of PRRSV
that are genetically and antigenically divergent from the
Figure 6 08 V194-neutralizing antibody titers (log2) after vaccination and 08 V194 challenge for group CON2 (Mock-vaccinated
control), 08 V194i (BEI-inactivated 08 V194), LVi2 (BEI-inactivated LV), 07 V063i2 (BEI-inactivated 07 V063) and PORatt2 (PorcilisW
PRRS). =primo vaccination;  = booster vaccination; "= challenge. Symbols represent individual animals and solid lines represent mean SN
titers calculated on all animals present in each group. The dashed line indicates the mean titers for all animals in group CON2. The dotted line
marks the detection limit for the SN test.
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current study was to assess the efficacy of experimental
BEI-inactivated vaccines, based on recent PRRSV field
isolates (07 V063 and 08 V194), against homologous and
heterologous challenge. A commercial inactivated (Pro-
gressisW) and two commercial attenuated (PorcilisW
PRRS and IngelvacW PRRS MLV) PRRSV vaccines were
included in the study and served as a reference. Vaccineefficacy was assessed by evaluating the viremia upon
challenge – a factor directly linked with viral pathogen-
esis and spread.
The 07 V063- and 08 V194-based inactivated PRRSV
vaccines were effective in partially protecting naïve pigs
upon homologous challenge. They shortened viremia
with 2 (07 V063) and 3 (08 V194) weeks compared to
the viremic phase in the respective mock-vaccinated
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LV vaccines were included to assess the impact of strain
variability on vaccine efficacy. We found no reduction in
07 V063 viremia after the use of an inactivated LV-based
vaccine and only a non-significant reduction of viremia
upon challenge with 08 V194. Similarly, a 07 V063-
based BEI-inactivated PRRSV vaccine did not signifi-
cantly reduce viremia upon challenge with the 08 V194
isolate. The ProgressisW vaccine did not provide any
virological protection, since viremia was observed for
4 weeks upon challenge with the 07 V063 isolate. This is
in line with the results from previous studies, showing
that the commercial inactivated vaccines appear not to
influence viremia, even in nearly homologous conditions
[21,24,27]. Vaccination with the EU-genotype attenuated
vaccine reduced the duration of viremia upon challenge
with 07 V063 with approximately one week. In animals
challenged with 08 V194, this vaccine shortened viremia
from 5 to 2 weeks. The NA-genotype attenuated vaccine
reduced viremia in 07 V063-challenged animals with ap-
proximately one week. Hence, despite the concerns
regarding the efficacy of the attenuated vaccine used on
both farms, the results of our study indicate that the use
of this vaccine in PRRS-naïve pigs can clearly limit
viremia. These results are in line with earlier studies
published by Cano et al. (2007) [28] and Scortti et al.
(2006) [29], showing that attenuated vaccines can be
successful in controlling and reducing clinical disease
upon homologous and heterologous challenge.
In the field, PRRSV vaccination is mainly performed in
sows. Therefore, we reasoned it would also be interest-
ing to assess the antibody response induced by the vac-
cines, since maternal antibodies play a pivotal role in the
passive (colostral) immunity that protects piglets during
their first weeks of life [30]. Although resolution of
PRRSV infection is not always directly correlated with
the neutralizing antibody response [31], there is ample
evidence that neutralizing antibodies can facilitate virus
clearance and, when present in sufficient amounts, may
even provide a sterilizing immunity [32-35]. IPMA and
SN tests were performed to evaluate the capacity of the
vaccines to induce or prime a challenge virus-specific
(neutralizing) antibody response.
Vaccination with BEI-inactivated 07 V063 or 08 V194
vaccines consistently induced sizable titers of homolo-
gous PRRSV-neutralizing antibodies after at least two
immunizations given four weeks apart. Interestingly,
vaccination with BEI-inactivated LV also induced
sizeable titers of 07 V063-neutralizing antibodies. Simi-
larly, both 07 V063- and LV-based vaccines induced
08 V194-neutralizing antibodies, with the LV-induced
titers being lower than the 07 V063-induced titers. In all
groups vaccinated with a BEI-inactivated vaccine, the
VN titers dropped immediately after challenge, whichmay indicate that the antibodies were consumed during
their interaction with virus early in infection. However,
after this initial drop in VN antibody titers, VN anti-
bodies quickly reappeared. The fast appearance of VN
antibodies upon challenge is in agreement with the find-
ings in the study of Vanhee et al. (2009) [25] and
demonstrates the potential of priming the neutralizing
antibody response by immunization with a high dose of
inactivated PRRSV. Although it has been reported that
the PRRSV-specific neutralizing antibody response is to
a large extent strain-specific and a lack in cross-
neutralization may occur even between genetically
closely related virus strains [36,37], our data show that
cross-neutralization between genetically different isolates
can occur. In the animals vaccinated with the commer-
cial inactivated PRRSV vaccine ProgressisW (first experi-
ment), neither the IPMA nor the VN antibody response
was influenced before or after challenge with 07 V063.
This is in line with the studies by Zuckermann et al.
(2007) [24] and Vanhee et al. (2009) [25], where they
used the same vaccine and the LV strain as challenge
virus: no clear induction of challenge virus-specific (neu-
tralizing) antibodies was observed upon vaccination with
the commercial inactivated PRRSV vaccine and only a
moderate anamnestic antibody response was observed
upon challenge of the vaccinated animals. The apparent
limited immunogenicity of this vaccine may relate to the
inactivation procedure used, strain variability, antigenic
dose, adjuvant, . . . Further research is necessary to eluci-
date this. In the animals vaccinated with the commercial
attenuated vaccines, either based on EU- (PorcilisW
PRRS) or NA- (IngelvacW PRRS MLV) type virus, a low
or non-detectable VN antibody response was observed,
which is in agreement with the results of Lopez et al.
(2004) [33]. None of the attenuated vaccines were able
to induce a faster neutralizing antibody response upon
challenge. The data obtained in this study have provided
the basis for an ongoing field study on the effect of dif-
ferent vaccines at the farm level, more specifically on the
effects of vaccination of sows on the passive immunity
transferred to piglets.
In the 07 V063- and 08 V194-challenged groups vacci-
nated with a BEI-inactivated vaccine homologous to the
challenge virus, a correlation was seen between the in-
duction of virus-specific neutralizing antibodies and re-
duction in viremia, indicating that VN antibodies may
contribute to protection against the virus. However, the
induction of homologous VN antibodies was not suffi-
cient to completely protect the animals, as it still permit-
ted the development of a viremia post-challenge that
lasted at least one week. Possibly, higher VN antibody
titers are needed at the time of challenge to offer full
protection against the high dose of virus used to infect
the animals. Administration of a heterologous BEI-
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duce viremia in the animals upon challenge. Since the
BEI-inactivated vaccines used in this study induced anti-
bodies that could neutralize the homologous as well as
the heterologous challenge virus in in vitro seroneutrali-
zation assays, it was somewhat surprising that these vac-
cines could only limit viremia under the homologous
challenge conditions, and not when the heterologous
challenge virus was used. The exact reason behind this
remains currently unknown, but several possible expla-
nations suggest themselves. For instance, it is possible
that induction of virus-specific neutralizing antibodies is
not sufficient and that BEI-inactivated PRRSV vaccines
must promote other immune mechanisms (e.g. via
cross-presentation to T-cells) to provide a significant de-
gree of protection upon challenge. On the other hand, it
can be speculated that, although the vaccine-induced
antibodies can bind and neutralize the homologous and
heterologous challenge virus to a similar extent in
in vitro SN assays, they recognize the homologous virus
with a higher affinity. Affinity differences may explain a
reduced binding and neutralization of heterologous virus
in vivo, as the binding conditions for (VN) antibodies
are likely more stringent in vivo than in the in vitro SN
assays. Under homologous challenge conditions, the
antibodies have undergone optimal challenge virus-
specific affinity maturation, while this is not the case
under heterologous challenge conditions. In theory, the
presence of vaccine-induced antibodies that cross-react
with a heterologous challenge virus may even prevent
the selection of high-affinity (VN) antibodies against this
challenge virus (original antigenic sin). Clearly, this mat-
ter requires further investigation in the future. Despite
the absence of a clear challenge virus-specific VN anti-
body response, the commercial attenuated vaccines do
provide a partial virological protection, roughly similar
to the protection provided by the autogenous BEI-
inactivated vaccines. This observation points towards a
significant role of other attenuated vaccine-induced im-
mune mechanisms (e.g. cell-mediated immunity) in the
protection against PRRSV infection [24,31,38]. Vaccin-
ation with the commercial inactivated vaccine Progres-
sisW did not induce VN antibodies and neither did it
provide any degree of protection upon challenge.
Considering the similar efficacy of the attenuated vac-
cines against both challenge isolates used in this study, it
can be questioned whether the use of autogenous inacti-
vated vaccines is advantageous over the use of the
current attenuated vaccines. However, while the efficacy
of the attenuated vaccines against new virus variants can
be unpredictable, our data demonstrate that an (adapt-
able) autogenous BEI-inactivated vaccine can provide a
more or less standardized, predictable degree of protec-
tion against a specific virus variant, which may proveuseful in case virus variants emerge that escape the im-
munity induced by the attenuated vaccines. In the near
future, additional research will be conducted to further
substantiate this. Also, although the production of au-
togenous inactivated vaccines as described in this study
may appear too elaborate and costly (virus isolation,
adaptation to cell culture, high dose needed,. . .), further
optimization of the production process should make fu-
ture use of these vaccines more feasible.Conclusions
The current study assessed the protective capacity of dif-
ferent experimental and commercial vaccines against
challenge with two recent PRRSV field isolates. Experi-
mental BEI-inactivated vaccines based on these field iso-
lates significantly shortened viremia upon homologous
challenge. Despite the concerns regarding the efficacy of
the commercial attenuated vaccines used on the farms
where the field isolates were obtained, use of commercial
attenuated vaccines resulted in a similar reduction of the
viremic phase. In contrast, the experimental BEI-
inactivated vaccines did not significantly reduce viremia
upon heterologous challenge and the commercial inacti-
vated vaccine had no apparent effect.
While the BEI-inactivated vaccines (both homologous
and heterologous) induced challenge virus-specific neu-
tralizing antibodies, this was not the case for the com-
mercial inactivated and attenuated vaccines. The results
illustrate that the capacity of a vaccine to induce chal-
lenge virus-specific neutralizing antibodies does not ne-
cessarily correlate with protection against the challenge
virus and vice versa, suggesting that not only vaccine-
induced antibodies, but also other vaccine-induced im-
mune mechanisms can contribute to PRRSV-specific
protective immunity.
The observation that homologous BEI-inactivated vac-
cines can provide a more or less standardized, predict-
able degree of protection against a specific virus variant
suggests that such vaccines may prove useful in case
virus variants emerge that escape the immunity induced
by the attenuated vaccines. Future research will allow
optimization and simplification of the production
process of the adaptable BEI-inactivated vaccines and
give further insights into the mechanisms of protection
induced by these vaccines.Methods
Cells and viruses
Porcine alveolar macrophages (PAMs) were derived from
3-week-old (just weaned) piglets, purchased from a
PRRSV- and Mycoplasma Hyopneumoniae-negative
farm. After isolation, the morphology of PAMs was
checked visually via light microscopy. No specific tests
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cells were cultivated as described before [39].
The Belgian PRRSV isolates used in this study origi-
nated from two farms showing clinical signs compatible
with PRRS in sows or growing pigs. The two isolates
were randomly selected from 19 isolates obtained be-
tween 2007 and 2010. At the moment of sampling, sows
of both herds were vaccinated with a EU-genotype atte-
nuated vaccine (PorcilisW PRRS). PRRSV isolate 07 V063
was isolated from fetal tissue by inoculating tissue sus-
pensions on PAM. This isolate has been used in recent
studies by Karniychuk et al. (2011; 2012) [40,41], de-
scribing viral, clinical and pathological data. Similarly,
the 08 V194 isolate was obtained by inoculating the
serum of 14-week-old piglets on PAM. Both isolates
were also adapted to MARC-145 cells by repeated pas-
sages. For challenge, macrophage-grown stocks were
prepared of the isolates 07 V063 (2nd passage on PAM)
and 08 V194 (5th passage on PAM).
For vaccine preparation, MARC-145 cell culture super-
natants of 07 V063 (2nd passage on PAM+2 passages on
MARC-145), 08 V194 (2nd passage on PAM+4 passages
on MARC-145) and LV (2nd passage on PAM+5 passages
on MARC-145), were purified via ultracentrifugation as
previously described by Vanhee et al. (2009) [25].
Genome sequencing and phylogenetic analysis
To determine if adaptation to the MARC-145 cell line
resulted in mutations in the structural ORFs, ORF2-7 of
MARC-145-grown 07 V063, 08 V194 and LV were
sequenced and compared with those of original
macrophage-grown 07 V063, 08 V194 and LV. Sequen-
cing was performed as described before [42]. Nucleotide
sequences were submitted to Genbank under accession
numbers [GenBank: GU737264] (07 V063) and [Gen-
Bank: GU737265] (08 V194).
Amino acid (aa) sequences were subsequently derived
and analysed using CLC Free workbench 4. The aa
sequences of all structural proteins of MARC-145-grown
07 V063, 08 V194 and LV were 100% identical to those
of the corresponding proteins of original macrophage-
grown virus. The clear difference in aa sequence be-
tween both 07 V063 and 08 V194 and the PorcilisW
PRRS strain allowed their classification as EU wild-type
viruses that are not of vaccine origin.
Virus inactivation and quality control
Purified virus (07 V063, 08 V194 and LV) was suspended
in RPMI 1640 (Invitrogen) to a titer of 108 TCID50/mL.
Subsequently, the virus was inactivated using BEI as
described before [25], and inactivated virus was stored at
−70°C. To confirm that all virus was completely inacti-
vated, a complete vaccine dose of 07 V063, 08 V194 and
LV was inoculated on MARC-145 cells and subsequentlypassaged twice. As a positive control, MARC-145 cells
were inoculated with 1 mL of non-inactivated 07 V063,
08 V194 or LV. The MARC-145 cells were routinely
checked for cytopathic effect (CPE) and ultimately stained
for the PRRSV nucleocapsid protein via an immunoperox-
idase staining using monoclonal antibody 13E2 [43]. No
CPE or positive nucleocapsid staining was detected in cells
that were inoculated with inactivated virus, while clear
CPE and nucleocapsid staining were observed in cell cul-
tures that were inoculated with non-inactivated virus.
Since conservation of entry of inactivated virus may
serve as a quality control for the preservation of antigenic
properties, the effect of BEI inactivation on virus attach-
ment and internalization into macrophages was examined
as described previously [25,44]. Non-inactivated virus sus-
pensions were included as positive controls. The entry ex-
periment showed that the binding and internalization
kinetics of all BEI-inactivated virus stocks are similar to
those observed for the non-inactivated virus stocks.
Pigs and experimental design
Sixty-seven four-week-old piglets were purchased from a
PRRSV-negative farm and their PRRSV-seronegative sta-
tus was confirmed by IPMA upon arrival. The animals
were housed in isolation units with HEPA-filtered air
and kept during 7 days to allow adaptation to the new
conditions. Two experiments were performed (Table 1).
All animal experiments were approved by the local eth-
ical committee of the Faculty of Veterinary Medicine,
Ghent University.
Vaccination experiment with PRRSV isolate 07 V063
Thirty-six pigs were randomly divided into six groups.
An oil-in-water (o/w) diluent, normally used in the com-
mercial pseudorabies virus vaccine Suvaxyn Aujeszky
(Fort Dodge Animal Health), was used as an adjuvant
and is further referred to as o/w Suvaxyn. A first group
(group CON, n= 6 pigs) served as a mock-vaccinated
control group and received 1 mL RPMI 1640 in 1 mL o/
w Suvaxyn intramuscularly at 5 and 9 weeks of age.
Three other groups were vaccinated twice intramuscu-
larly at 5 (primo vaccination) and 9 (booster vaccination)
weeks of age. Group 07 V063i (n= 6 pigs) was vacci-
nated with 1 mL BEI-inactivated MARC-145-grown
07 V063 (108 TCID50) in 1 mL o/w Suvaxyn and group
LVi (n= 6 pigs) was vaccinated with 1 mL BEI-
inactivated MARC-145-grown LV (108 TCID50) in 1 mL
o/w Suvaxyn. Group PROi (n= 6 pigs) received 2 mL of
a commercial European type inactivated PRRSV vaccine
(ProgressisW, Merial, strain P120: min 2,5 log IF Units).
Groups PORatt (n= 6 pigs) and INGatt (n= 6 pigs) were
vaccinated once intramuscularly with the European type
attenuated vaccine (PorcilisW PRRS, Intervet, 104
TCID50/2 mL) and the American type attenuated
Table 1 Experimental design of vaccination-challenge
experiments
Group Vaccination Age in
weeks
Challenge strain
(13 weeks)
Experiment
1 (n)
CON (6) Mock 5 and 9 07 V063
07 V063i (6) BEI-inactivated 07 V063 5 and 9 07 V063
LVi (6) BEI-inactivated LV 5 and 9 07 V063
PROi (6) ProgressisW 5 and 9 07 V063
PORatt (6) PorcilisW PRRS 7 07 V063
INGatt (6) IngelvacW PRRS 7 07 V063
Experiment
2 (n)
CON2 (7) Mock 5 and 9 08 V194
08 V194i (6) BEI-inactivated 08 V194 5 and 9 08 V194
LVi2 (6) BEI-inactivated LV 5 and 9 08 V194
07 V063i2 (6) BEI-inactivated 07 V063 5 and 9 08 V194
PORatt2 (6) PorcilisW PRRS 7 08 V194
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104.9 TCID50/2 mL), respectively, at the age of 7 weeks.
At 13 weeks of age, all pigs were challenged intranasally
with PRRSV 07 V063 (106 TCID50) in phosphate buf-
fered saline (PBS) (2,5 ml per nostril). Blood samples
were taken by jugular venipuncture weekly after (primo)
vaccination and at 0, 1, 3, 5, 7, 10, 14, 21, 28, 35 and
42 dpc. Serum was collected and stored at −70°C. Serum
samples for IPMA and VN antibody detection were
incubated for 30 min at 56°C prior to freezing.Vaccination experiment with PRRSV isolate 08 V194
In a second experiment, 31 piglets were randomly
assigned to five treatment groups. Group CON2 (n= 7
pigs) served as a mock-vaccinated control group and
received 1 mL RPMI 1640 in 1 mL o/w Suvaxyn intra-
muscularly at 5 and 9 weeks of age. Three other groups
were vaccinated twice intramuscularly at 5 (primo vac-
cination) and 9 (booster vaccination) weeks of age.
Group 08 V194i (n= 6 pigs) was vaccinated with 1 mL
BEI-inactivated MARC-145-grown 08 V194 (108 TCID50)
in 1 mL o/w Suvaxyn, group LVi2 (n= 6 pigs) was vacci-
nated with 1 mL BEI-inactivated MARC-145-grown LV
(108 TCID50) in 1 mL o/w Suvaxyn and group
07 V063i2 (n= 6 pigs) was vaccinated with 1 mL BEI-
inactivated MARC-145-grown 07 V063 (108 TCID50) in
1 mL o/w Suvaxyn. At 7 weeks of age, pigs of group
PORatt2 (n= 6 pigs) were vaccinated intramuscularly
with PorcilisW PRRS at a dose of 104 TCID50 per pig.
PRRSV-isolate 08 V194 at a dose of 106 TCID50 was
used to inoculate all pigs intranasally (2,5 ml per nostril)at the age of 13 weeks. The same experimental design
was used as in the first experiment.
Virus titration and serological examinations
Virus titers in serum were determined by virus titration
on PAM following a standard procedure [32]. 24-h culti-
vated PAM were inoculated with 10-fold dilution series
of the serum samples. 72 hours post inoculation, cells
were fixed and an immunoperoxidase staining with
monoclonal antibody 13E2 against the PRRSV nucleo-
capsid protein was performed to visualize infection in
the cells [43]. The titers were calculated as described by
Reed and Muench (1938) [45] and expressed as TCID50/
mL. To check the sensitivity of the PAM, all cell batches
were assayed in virus titrations using a PRRSV stock
(LV) with a known virus titer.
Serum samples were examined for the presence of
PRRSV-specific antibodies using an IPMA as described
by Labarque et al. (2000) [32]. To detect antibodies
against 07 V063 (1st experiment), an IPMA was per-
formed on 07 V063-infected MARC-145 cells. To detect
antibodies against 08 V194 (2nd experiment), an IPMA
was performed on 08 V194-infected MARC-145 cells.
VN antibodies were detected by seroneutralization
assays on MARC-145 cells using the respective PRRSV
challenge isolate. Each serum sample was tested in du-
plicate. Briefly, serum samples were twofold serially
diluted and an equal volume of a PRRSV 07 V063 (2nd
passage on PAM+2 passages on MARC-145) or
08 V194 (2nd passage on PAM+4 passages on MARC-
145) suspension (titer 2 × 103 TCID50/mL) was added to
each dilution. After mixing, the plates were incubated at
37°C for 1 h and 50 μl of the mixture was subsequently
transferred to confluent monolayers of MARC-145 cells
in 96-well plates. Cells were screened for 7 days after in-
oculation and the neutralization titer of the sera was
recorded as the reciprocal of the highest dilution that
inhibited CPE in 50% of the inoculated wells. To check
the sensitivity to PRRSV infection of different passages
of MARC-145 cells, control titrations using PRRSV
stocks (isolate 07 V063 and isolate 08 V194) with a
known virus titer were performed in parallel with each
neutralization assay.
Statistical analysis
Antibody titers and virus titers were analyzed by
Kruskall-Wallis test, followed by Dunn’s multiple com-
parisons test to determine significant differences with
the control groups at different time points. Samples, that
tested negative in IPMA, VN or virus isolation were
consequently given a numerical value of 0.0. A two-
tailed Fisher’s exact test was used to determine signifi-
cant differences between the number of viremic animals
in the vaccinated groups and the control groups at
Geldhof et al. BMC Veterinary Research 2012, 8:182 Page 15 of 16
http://www.biomedcentral.com/1746-6148/8/182different time points. An overall p value of 0.05 was
taken as the level of statistical significance. All statistical
analyses were performed using GraphPad Prism version
5.0a (GraphPad Software, San Diego, California, USA).
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